The abstracts presented at the 2016 Towards an HIV Cure Sympsoium are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.
Viral diversity, phylogenetics and phylodynamics
P1: Analysis of Intra-patient, Full Length HIV gag Sequences Identifies Regions of Variability
Elizabeth Anderson
National Cancer Institute at Frederick, United States
Antibody diversity and function
P2: Increased interferon-alphaactivity may contribute to defects of B cells and antibody production caused by HIV-1 infection
Martyn French
University of Western Australia, Australia
Reverse transcription and integration
P3: HIV infected patients with exceptional TCD4+ recovery during effective HAART present a distinct T CD4+ differentiation pattern, higher CD31neg naïve cells and a smaller HIV reservoir
Santiago Perez-Patrigeon
INCMNSZ, Infectious Diseases, Mexico
HIV-1 controllers (including post-treatment controllers)
P4: Post-treatment Control or Treated Controllers? The impact of ART on time to viral rebound in recent seroconverters
Genevieve E. Martin
University of Oxford, United Kingdom
P5: Identification of different HIV-controller phenotypes: looking for the right model of functional cure
Beatriz Dominguez-Molina
Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Spain
P6: HIV Virological Controllers in an African Cohort
Yumna Moosa
CAPRISA, South Africa
Correlates of immune protection
P7: Presence of HIV-1C broadly neutralizing antibodies in pregnancy and at delivery
Takafira Mduluza
University of Zimbabwe, Zimbabwe
Viral mechanisms of HIV/SIV persistence and latency
P8: IFNα activates latent HIV-1 in non-proliferating latently infected T-cells
Renee Marije van der Sluis
Doherty Institute for Infection and Immunity, University of Melboure, Australia
Poster
P9: HIV-1 Disrupts Mitochondrial Dynamics: Induces Fission and Mitophagy to Attenuate Apoptosis in Astrocyte (Late Breaker)
Diego Sebastian Ojeda
INBIRS, Microbiologia, Argentina
Host cellular factors and latency
P10: The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency
Filippo Turrini
Vita-Salute San Raffaele University, Italy
P11: Identification of a new host cell HDAC complex that controls HIV latency through direct binding to the core promoter
Emmanuelle Wilhelm
Université de Sherbrooke, Canada
Cellular and tissue reservoirs of HIV/SIV
P12: Persistence of HIV DNA in Seminal Plasma Fraction after ART among Men who have Sex with Men and Transgender Women in the Thailand Test &Treat Cohort
Eleanore Chuang
University of Hawaii, United States
Poster
P13: Memory CD4+ T cells expressing HLA-DR contribute to HIV persistence during prolonged ART
Eunok Lee
The Westmead Institute for Medical Research, University of Sydney, Australia
Poster
P14: Effect of Substances of Abuse on HIV DNA Decay during Antiretroviral Therapy Started During Early HIV Infection
Sara Gianella
University of California San Diego, United States
P15: Is the lung a site of productive HIV infection that persists through ART?
David Russell
Cornell University, United States
P16: Whole-body SPECT in Vivo Imaging reveals delayed reconstitution of lymph-nodes, but not spleen, CD4 pools in long-term cART treated animals (Late Breaker)
Michele Di Mascio
Division of Clinical Research, NIAID, NIH, United States
Measurement of HIV/SIV reservoirs
P17: HIV proviral DNA quantification in a cohort of Japanese patients on long-term ART
Kamelia Stanoeva
Kumamoto University, Center for AIDS Research, Japan
Poster
P18: Initiation of ART within 24-48 hours of birth following in utero HIV infection - the Ucwaningo Lwabantwana Study
Julia Roider
University of Oxford, United Kingdom
Poster
P19: Quantification and correlates of the replication competent HIV-1 latent viral reservoir in a virally suppressed Ugandan population
Jessica L. Prodger
National Institute of Allergy and Infectious Diseases, NIH, United States
Targeting and eradication of reservoirs
P20: Sirtuin1 Inhibitor Nicotinamide disrupts HIV-1 Latency
Sadia Samer
Federal University of Sao Paulo, Brazil
P21: T regulatory cell depletion in controller macaques reactivates SIV and boosts CTLs
Tianyu He
University of Pittsburgh, United States
P22: Development of DOUBLE NICKASE CRISPR Aganist Latently Infected Human Immunodeficency Virus (HIV)
Oluwaseun Ayodeji Ishola
Advanced medical and dental institute, Universiti Sains Malaysia, Malaysia
Poster
P23: Understanding the effects of latency reversing agents on HIV RNA splicing - implications for latency reversal
Talia M. Mota
University of Melbourne, Doherty Institute for Infection and Immunity, Australia
P24: Thalidomide Reverses Latency of HIV-1 Provirus
Sadia Samer
Federal University of Sao Paulo, Brazil
P25: Targeting HSF1-mediated stress response can enhance Hsp90 inhibitor-induced suppression of HIV-1 reactivation from latency
Alexander Kabakov
Biomedical Research Center, Russian Federation
P26: A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
Hao Lu
Peter Doherty Institute, University of Melbourne, Australia
P27: Therapeutic immune recovery prevents emergence of CXCR4-tropic HIV-1
Thomas Klimkait
University of Basel, Switzerland
Poster
P28: Dendritic cells programmed by inflammatory mediators can effectively induce both the immunologic 'kick' and 'kill' of latent HIV-1
Jan Kristoff
University of Pittsburgh, United States
P29: In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels, and latent HIV infection
Perry Tsai
University of North Carolina at Chapel Hill, United States
P30: Maraviroc administration is associated to reversion of latent HIV-1 through NFkB in ART suppressed patients (Late Breaker)
Santiago Moreno Guillén
Hospital Ramón y Cajal, Spain
Acute and early infection
P31: Systematic Review of the Current Literature on Structured Treatment Interruptions in HIV-infected Patients Receiving Antiretroviral Therapy - Implications for Future HIV Cure Trials
Melanie Stecher
University Hospital of Cologne, Germany
P32: Alarmin IL-33/ST2 pathway as an inductor of T-cell dependent response in acute and early HIV-infected patients
Jean-Pierre Routy
McGill University Health Centre, Canada
Novel approaches in Immunotherapeutics (including bnAbs and anti-inflammatory mediators)
P33: A novel bispecific immunoadhesin displays enhanced breadth and potency against diverse HIV-1 subtypes in vitroand in humanized mice
Xilin Wu
AIDS Institute, The University of Hong Kong, Hong Kong
P34: Novel Conserved Element HIV/SIV DNA Vaccines Maximize Breadth and Magnitude of Immune Response
Barbara K. Felber
National Cancer Institute at Frederick, United States
Poster
Targeting HIV persistence during ART (cure strategies)
P35: Therapy with The Immunomodulatory Agent Pomalidomide Does Not Lead To Changes In HIV-1 Viral Populations In Vivo
Sarah A. Watters
University College London, United Kingdom
P36: Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
Xiao Mei T. Kuang
Simon Fraser University, Canada
P37: Novel pathways of Tat expression identify new targets for reactivation of latent HIV-1
Michelle Lee
University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Australia
P38: Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
Elisa De Crignis
Erasmus MC, Netherlands
P39: Novel activators and suppressors of latent HIV-1 from natural products
Ian Tietjen
Simon Fraser University, Canada
P40: A systems dynamics approach to identifying novel HIV treatments
Hua Yang
Cooper Human Systems, United States
Poster
P41: Vitamin D level in cART treated patients is critical for HIV reservoir size
Christine Rouzioux
Necker Hospital, France
Therapeutic vaccines
P42: Characterization ofMonocyte-Derived Dendritic Cells Used in Immunotherapy for HIV-1-infected Individuals
Lais Teodoro da Silva
Faculdade de Medicina da Universidade de Sao Paulo, Brazil
P43: siRNA based TLR7/8 activation, MHC class I recycling from endosome and cross presentation of HIV-1 antigen for elevated CD8+ response: An approach for intracellular vaccine
Birendra Gupta
Tribhuvan University, Nepal
P44: Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya
Borna Achieng Nyaoke
KAVI-Institute of Clinical Research, University of Nairobi, Kenya
P45: HIV-tat fused to the oligomerisation domain of the c4-binding protein is highly immunogenic and controls EcoHIV challenge in mice
Khamis Tomusange
University of Adelaide, Australia
Novel animal/virus models for vaccine, cure research, and inhibitor development
P46: A nonhuman primate model of fully MHC-matched allogeneic stem cell transplantation to study HIV reservoir clearance (Late Breaker)
Ben Burwitz
Oregon Health & Science University, Vaccine & Gene Therapy Institute, United States
Poster
Animal models of latency reservoirs and eradication
P47: Immuno-PET/CT imaging reveals differences in virus and CD4+ cell localization in SIV infected rhesus macaques treated with an anti-α4β7 mab
James Arthos
National Institute of Allergy and Infectious Diseases, NIH, United States
Acute and early infection
P48: Faster restoration of CD4:CD8 ratio during the first 12 weeks of ART initiated at early HIV infection compared with ART initiated at chronic infection in the same patients
Alexander Pasternak
Academic Medical Center of the University of Amsterdam, Netherlands
Poster
P49: Using ddPCR to Assess Persistence of HIV DNA Reservoirs in Perinatally Infected Infants Treated with cART Before or After 12 Months of Age
Priya Soni
UCLA - David Geffen School of Medicine, United States
Poster
P50: Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection (Late Breaker)
Eugene Kroon
SEARCH, The Thai Red Cross AIDS Research Centre, Thailand
Ethical issues in clinical trials and treatment strategies
P51: HIV patients and caregivers viewpoints towards participation to future HIV Cure-related clinical trials - results from the second part of the French ANRS-APSEC survey
Marie Suzan-Monti
INSERM, UMR_S 912, France
Poster
P52: How to keep high-risk early-phase HIV cure and long-term remission studies ethical: classifying candidate solutions
Nir Eyal
Harvard TH Chan School of Public Health, United States
Social and behavioural concepts and theories
P53: Perceptions of HIV remission (“cure”) trials and trial intentions among potential participants treated in acute HIV infection
Thidarat Jupimai
SEARCH, The Thai Red Cross AIDS Research Center, Thailand
P54: How curing HIV could influence stigma: a qualitative analysis of men who have sex with men in Guangzhou, China
Feng Wu
UNC Project-China, China
Poster
Community engagement in research and research dissemination
P55: “I can coexist with HIV”: a qualitative study of perceptions of HIV "cure" among people living with HIV in Guangzhou, China
Feng Wu
UNC Project-China, China
Poster
Ethical aspects and standards, including with respect to research, clinical services, public health policy and programmes, and professional conduct
P56: Is there an implementation ethics to HIV cure-related research?
Karine Dube
University of North Carolina at Chapel Hill, United States
P57: HIV Cure research: a survey of Australian people living with HIV onperspectives, perceived benefits and willingness to participate in trials
Jennifer Power
La Trobe University, Australia
P58: Challenges in developing an educational video on HIV Cure research
Ciara Staunton
Stellenbosch University, Centre for Medical Ethics and Law, South Africa
Poster
P59: Interrupting HIV Treatment in Cure Research: Scientific and Ethical Considerations
Jeremy Sugarman
Johns Hopkins University, United States